key: cord-1054343-w4e7adtv
authors: LI, Y.; JIANG, Y.; ZHANG, Y.; LI, N.; YIN, Q.; LIU, L.; LV, X.; LIU, Y.; LI, A.; FANG, B.; LI, J.; YE, H.; YANG, G.; CUI, X.; QU, Y.; LI, C.; LI, D.; WANG, S.; GAI, Z.; ZHAN, F.; LIANG, M.
title: Abnormal Upregulation of Cardiovascular Disease Biomarker PLA2G7 Induced by Proinflammatory Macrophages in COVID-19 patients
date: 2020-08-18
journal: nan
DOI: 10.1101/2020.08.16.20175505
sha: 134b2171a534e1b0157d02a57e21b9f2c4abdb7f
doc_id: 1054343
cord_uid: w4e7adtv

BACKGROUND. Coronavirus disease 2019 (COVID-19) triggers distinct patterns of pneumonia progression with multiorgan disease, calling for cell- and/or tissue-type specific host injury markers. METHODS. An integrated hypothesis-free single biomarker analysis framework was performed on nasal swabs (n=484) from patients with COVID-19 in GSE152075. The origin of candidate biomarker was assessed in single-cell RNA data (GSE145926). The candidate biomarker was validated in a cross-sectional cohort (n=564) at both nucletide and protein levels. RESULTS. Phospholipase A2 group VII (PLA2G7) was identified as a candidate biomarker in COVID-19. PLA2G7 was predominantly expressed by proinflammatory macrophages in lungs emerging with progression of COVID-19. In the validation stage, PLA2G7 was found in patients with COVID-19 and pneumonia, especially in severe pneumonia, rather than patients suffered mild H1N1 influenza infection. The positive rates of PLA2G7 ranging from 29.37% to 100.00% were positively correlated with not only viral loads in patients with COVID-19 but also severity of pneumonia in non COVID-19 patients. Although Ct values of PLA2G7 in severe pneumonia was siginificantly lower than that in moderate pneumonia (P=7.2e-11), no differences were observed in moderate pneumonia with COVID-19 between severe pneumonia without COVID-19 (P=0.81). Serum protein levels of PLA2G7, also known as lipoprotein-associated phospholipase A2 (Lp-PLA2), were further found to be elevated and beyond the upper limit of normal in patients with COVID-19, especially among the re-positive patients. CONCLUSIONS. We firstly identified and validated PLA2G7, a biomarker for cardiovascular diseases (CVDs), was abnormally enhanced in COVID-19 patients at both nucletide and protein aspects. These findings provided indications into the prevalence of cardiovascular involvements seen in COVID-19 patients. PLA2G7 could be a hallmark of COVID-19 for monitoring disease progress and therapeutic response.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel enveloped 67 RNA betacoronavirus that emerged in December 2019 in Wuhan, China, and is the 68 causative etiology of coronavirus disease 2019 (COVID-19)(1, 2). Typical clinical 69 presentation of COVID-19 was a lung involvement, as evidenced by image tests, with 70 fever, cough and dyspnea(3, 4). Severe cases often developed acute respiratory distress 71 syndrome (ARDS) or even death(3, 4). The risk factors for increased disease severity 72 in patients with COVID-19 has been reported as older age (e.g., over 50 years old) and 73 the presence of comorbidities, including hypertension, diabetes mellitus, cardiovascular 74 disease etc.(5, 6). However, it rapidly became obvious that severe COVID-19 can also 75 occur in younger patients with no pre-existing comorbidities(7). 76 77 On-going data characterizing immunological features in patients with COVID-19 were 78 starting to emerge. Host response to SARS-CoV-2 infection was distinct in comparison 79 with other highly pathogenic coronaviruses and common respiratory viruses in cell 80 lines(8). Notably, reduced type I interferon activities were observed in both in vitro (8) 81 and in vivo(9) data. Delayed production of type I interferon resulted in boosted 82 cytopathic effects (CPE) and increased sensing of SARS-COV-2 threats promoted the 83 enhanced release of monocyte chemoattractants, such as CCL2(10), which contributed 84 an influx of monocytes into lungs(7). Autopsy studies have shown diffuse thickening 85 of the alveolar wall with mononuclear cells and macrophages infiltrating airspaces(11). 86 However, it is still mysterious why there were various complications of 87 including impaired function of the organs, especially heart(7). Among 1,216 88 hospitalized COVID-19 patients across 69 countries who did not have pre-existing 89 heart complications, almost half showed scan abnormalities that resemble the early 90 stages of heart failure(12). 91 92 Hypothesis-free biomarker studies could allow researchers to gain in depth insights into 93 patho-mechanisms underlying COVID-19. Several attempts have been made. 94

Expression of monocyte CD169 (mCD169), also known as sialic acid binding Ig like 95 lectin 1 (SIGLEC1), has been suggested as a biomarker in the early diagnosis of 96 COVID-19(13). But expression of SIGLEC1 could be enhanced by other viruses(14). 97 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 18, 2020. showed PLA2G7 was expressed principally by macrophages (Figure 2A is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 18, 2020. . https://doi.org/10.1101/2020.08.16.20175505 doi: medRxiv preprint 6 S10-11). It was worth of noting that the expression profile of PLA2G7 shared a close 161 pattern to SPP1 ( Figure 2D ), which played an important role in idiopathic pulmonary 162 fibrosis(28). Macrophages with FABP4, also known as the alveolar macrophages, were 163 reduced with progression of COVID-19 while macrophages with FCN1 and SPP1, 164 considered as the proinflammatory macrophages, were strikingly increased ( Figure 2E) . 165

In addition, strong correlation between expression of PLA2G7 and progression of 166 COVID-19 was discovered (r = 0.927, P = 1.4e-4) ( Figure 2F ). On the whole, PLA2G7 167 was predominantly expressed by these proinflammatory macrophages emerging along 168 with progression of COVID-19. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 18, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 18, 2020. . https://doi.org/10.1101/2020.08.16.20175505 doi: medRxiv preprint 8 necessary to better identify biomarkers, especially these represented the therapeutic and 224 diagnostic targets. It has been suggested that cytokine blood RNA level was not always 225 correlated with the protein plasma level(9). We therefore applied our previous 226 established hypothesis-free single biomarker analysis framework on nasal swabs from 227 more than 400 donors with COVID-19 in GSE152075. Finally, upregulated PLA2G7, 228 a biomarker for cardiovascular diseases (CVDs)(29), was identified as a hub gene in 229 SARS-COV-2 infection (Figure 1) . Coincidentally, phospholipase A2 Group IID 230 (PLA2G2D), belonged to the same PLA2 superfamily as PLA2G7 did, was considered 231 as an increase factor to result in worse outcomes of mice infected by SARS-CoV(30). 232

In addition, a 12-year follow-up survey of 25 patients who recovered from SARS-CoV 233 infection found that 44% had cardiovascular system abnormalities(31) while almost 234 half of hospitalized COVID-19 patients showed scan abnormalities that resemble the 235 early stages of heart failure(12). 236

To understand the origin of PLA2G7, we re-analyzed scRNA-seq data from COVID-237 19 patients BALFs in GSE145926. We presented evidence-based findings that 238 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 18, 2020. . https://doi.org/10.1101/2020.08.16.20175505 doi: medRxiv preprint 9 macrophages in lungs played central roles in pneumonia(34), we postulated that 256 PLA2G7 could be detected in not only patients with COVID-19, but also patients with 257 pneumonia. The positive rate of PLA2G7 in nasal swabs from donors with pneumonia 258 was higher than that in health controls and patients suffered seasonal influenza infection 259 ( Figure 3C ). It was worth of noting that 100% positive rate of PLA2G7 were observed 260 in severe pneumonia. In addition, the Ct values of PLA2G7 were significantly lower in 261 severe pneumonia than in moderate pneumonia (p = 7.2e-11). This was consistent with 262 our findings that expression of PLA2G7 was correlated with progression of COVID-19 263 ( Figure 2F is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 18, 2020. . https://doi.org/10.1101/2020.08.16.20175505 doi: medRxiv preprint worried to state that the mass of Lp-PLA2 in more than half (53.3%) of recovered 288 patients (n = 15) was beyond the upper limit of normal ( Figure 4A ). Coincidentally, a 289 recent study showed 78% of recovered COVID-19 patients, including illness ranging 290 from asymptomatic to moderate symptoms, suffered issues association with the 291 heart(38). Secondly, although the Lp-PLA2 was reduced along with time in hospitalized 292 COVID-19 patients, it should be noted that the plasma levels of Lp-PLA2 in these 293 patients were beyond the upper limit of normal, especially the moderate patients ( Figure  294 4B). According to National Health Commission of China (NHC), some of the patients 295 (later COVID-19 confirmed cases) first went to see a doctor because of cardiovascular 296 symptoms, rather than respiratory symptoms(39). Even without symptoms and signs of 297 interstitial pneumonia, cardiac involvement as a complication associated with COVID-298 19 has been reported (40) . Compare to severe group, the moderate patients who always 299 presented fewer and/or lighter symptoms of CVDs leaded to limited medical care on 300

CVDs. This might initiate follow-up comorbidities with heart in these patients. 301

To our knowledge, this is the first study that uncover the relationship between PLA2G7 302 and COVID-19 from both nucleotide and protein aspects. The results of our study 303 provide important indications into the prevalence of cardiovascular involvements seen 304 in COVID-19 patients, including status ranging from hospitalization to recovery period. 305

In addition, our findings reveal the aberrant profile of PLA2G7 persists beyond the 306 period of acute manifestation, especially in the discharged and re-positive patients. 307

Importantly, the expression profile of PLA2G7 in COVID-19 patients with moderate 308 pneumonia shows similar patterns seen in severe pneumonia, suggesting COVID-19 309 might enhance the expression of PLA2G7 (Figure 3 ). Although the long-term health 310 effects of role of PLA2G7 in COVID-19 cannot yet be determined, on-going 311 epidemiological evidence substantiated heart issues were occurred after COVID-19(41). is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 18, 2020. . https://doi.org/10.1101/2020.08.16.20175505 doi: medRxiv preprint information of clinical traits of samples, confounding factors, such as pre-existing 320

CVDs, which could increase the likelihood of PLA2G7 positivities, were not controlled. 321

The in-house qRT-PCR assay of PLA2G7 was not optimized, leading to inadequate 322 diagnostic performance. Most of the samples were retrospectively collected in Wuhan, 323

China. It has been almost several months passed since all the samples were collected. 324

The freshness of samples could also undermine the performance of the in-house 325 PLA2G7 targeted qRT-PCR and commercial Lp-PLA2 ELISA toolkit. 326 327 Taken together, we firstly identified proinflammatory monocytes-driven macrophages 328 specific PLA2G7 in lungs, a typically biomarker of CVDs, which leaded to abnormal 329 levels of plasma Lp-PLA2, was enhanced in COVID-19. Importantly, PLA2G7 was 330 detected in nasal swabs from patients with pneumonia. Although levels of PLA2G7 was 331 significantly elevated in severe pneumonia comparing to moderate pneumonia, there 332 were no significant differences between that in COVID-19 and severe pneumonia. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 18, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 18, 2020. . https://doi.org/10.1101/2020.08.16.20175505 doi: medRxiv preprint 13 (DO)(22) analyses were performed using clusterProfiler(43), identifying significant 380 results based on a P-value < 0.05 and gene counts ≥ 2. 381

The module that was most highly correlated with SARS-COV-2 infection was selected. 383

Candidate genes in the module were determined by both gene significance and module 384 membership. Thereafter, a single gene biomarker was selected using XGBoost with 385 recursive feature elimination with cross-validation (RFECV) (24, 25). 

Macrophages of all samples were re-integrated using the first 50 dimensions of 407 canonical correlation analysis and PCA with the parameter k.filter was set to 115. In 408 the clustering step, parameter resolution was set to 0.8. 409

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 18, 2020. . https://doi.org/10.1101/2020.08.16.20175505 doi: medRxiv preprint

Anti-inflammatory properties of a platelet-activating factor acetylhydrolase

Pathological inflammation in patients with COVID-606 19: a key role for monocytes and macrophages

The 609 role of macrophages in interstitial lung diseases: Number 3 in the Series 610 "Pathology for the clinician

Cardiovascular sequelae 613 of pneumonia

Pneumonia as a cardiovascular disease

Association between hospitalization for pneumonia and 618 subsequent risk of cardiovascular disease

Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently 621

Recovered From Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020

COVID-19 and the cardiovascular 623 system

Cardiac 625 Involvement in a Patient With Coronavirus Disease

Suspected myocardial 628 injury in patients with COVID-19: Evidence from front-line clinical observation 629

We enrolled nasal swabs from donors with health condition and diagnosis of COVID-411 19, influenza infection and pneumonia. In a total of 447 nasal swabs were collected. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted August 18, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted August 18, 2020. We acknowledge all health-care workers involved in the diagnosis and treatment of 495 patients in Wuhan and Jinan. We are grateful for all the patients for their supports and 496 confidence in our study. We thank the researchers who obtained the sequencing data 497 used in this study. We thank the helpful discussions with Xianbing YU from the 498 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted August 18, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted August 18, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted August 18, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted August 18, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted August 18, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted August 18, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted August 18, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted August 18, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted August 18, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted August 18, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted August 18, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted August 18, 2020. . https://doi.org/10.1101/2020.08.16.20175505 doi: medRxiv preprint